Conference Day One
Wednesday, December 3

7:30 am Check-In & Coffee

8:30 am Chair’s Opening Remarks

  • Fred Aslan President & Chief Executive Officer, Artiva Biotherapeutics, Inc

Comparing CAR-T & Emerging Modalities to Guide Modality Selection & Refine Therapeutic Strategy

8:40 am Industry Leaders Fireside Chat: Evaluating CAR-T in Comparison to Emerging Modalities to Refine Autoimmune Therapies Through Strategic Modality Selection

  • Fred Aslan President & Chief Executive Officer, Artiva Biotherapeutics, Inc
  • Samik Basu Chief Scientific Officer, Cabaletta Bio
  • Jennifer Chow Chief Executive Officer, iCell Gene Therapeutics
  • Naji Gehchan Chief Medical & Development Officer, Kyverna Therapeutics, Inc.
  • Clinton Weber Vice President, CMC Strategy, Umoja Biopharma

Synopsis

  • Explore the efficacy of differing modalities to identify opportunities where we can learn from other modalities
  • Compare modalities in their affinity for targeting autoreactive cells to minimize side-effects and enhance safety
  • Identify autoimmune indications where CD-19-CARs are suboptimal to spotlight opportunities for alternative therapeutic modalities

9:30 am Keynote Presentation: Showcasing Cabaletta Bio’s Rese-cel Data & Industry Implications to Progress CAR-T in Autoimmunity

  • Samik Basu Chief Scientific Officer, Cabaletta Bio

Synopsis

  • Explore rese-cel, a CAR-T cell therapy, combating autoimmune diseases to provide insight into the future of autoimmune cell therapies
  • Discuss how translational and mechanistic insights accelerated the design and development of rese-cel in autoimmunity
  • Evaluate the depth of peripheral and tissue-level target cell depletion with rese-cel in patients with autoimmune disease

10:00 am Morning Break & Speed Networking

Synopsis

As this community reunites, this session will provide valuable networking time with your peers, and new faces in the autoimmune space, enabling you to forge new and lasting connections.

Preclinical & Translational

Investigating Next-Generation Antibody Targeting Strategies to Enhance Precision & Efficacy

11:00 am Expanding CAR-T Targets Beyond CD-19 to Enhance Treatment Efficacy Across Autoimmune Diseases

  • Jeff Liter Chief Executive Officer, Luminary Therapeutics

Synopsis

  • Evaluate CD-19’s strengths and limitations as the anchor target for CAR-T treatment of autoimmune diseases
  • Explore novel targets to broaden the spectrum and complexity of treatable autoimmune diseases
  • Evaluate available targeting options to pinpoint optimal targets for varying autoimmune and autoinflammatory diseases

11:30 am Evaluating Opportunities to Engineer the Autoimmune Microenvironment to Sustain Target Engagement

  • Marko Radic, Ph.D. Associate Professor, Department of Microbiology, Immunology & Biochemistry, The University of Tennessee Health Science Center

Synopsis

  • Dissect microenvironmental factors that influence target accessibility and therapeutic cell performance
  • Tackle challenges in tonic signaling to secure ligand and graft antibody attachment and maintain therapeutic potency
  • Discuss strategies to generate a propitious microenvironment that enhances homing to receptors and sustains therapeutic effects

12:00 pm Reserved for Thermo Fisher Scientific

Clinical

Exploring Immune Cell Targeting to Enhance Treatment Efficacy & Durability

11:00 am Optimizing Immune Cell Target Selection to Deliver Effective Autoimmune Therapies

  • Shawn Rose Chief Medical Officer & Head, Research & Development, Nkarta Therapeutics

Synopsis

  • Evaluate which immune cell targets have demonstrated the greatest therapeutic benefits to guide treatment decisions
  • Understand patient tolerance to targeting alternative immune cells to optimize safety and efficacy
  • Leverage insights from Nkarta Therapeutics’ NK cell-based Non-Hodgkins Lymphoma therapy to predict autoimmune success

11:30 am Leveraging NK Therapies to Advance Autoimmune Cell Therapy Safety

  • Fred Aslan President & Chief Executive Officer, Artiva Biotherapeutics, Inc

Synopsis

  • Highlight the rationale and potential advantages of utilizing a non-genetically modified NK cell therapy in combination with monoclonal antibodies in autoimmune diseases
  • Explore clinical data demonstrating that NK cell therapies can drive deep B-cell depletion in autoimmune disease while avoiding side effects inherent in CAR-T and TCE therapies
  • Highlight a framework for selecting indications for different cell therapies based on their potential target product profile

12:00 pm Reserved for Promega Corporation

12:10 pm Lunch & Networking Break

Exploring Innovations in B-Cell Depletion & Beyond to Advance Immune Modulation

1:10 pm Exploring Autologous CD-19 CAR-Tregs for Rheumatology to Advance Treatment Development for Unmet Diseases

  • Luke Devey Chief Medical Officer, Quell Therapeutics

Synopsis

  • Explore the role of the immune system in rheumatoid scleroderma
  • Hear preclinical evidence from Quell Therapeutics on their novel therapy targeting rheumatoid scleroderma

1:40 pm Panel Discussion: Comparing Immune Cell Depletion & Immune Tolerance Therapies to Accelerate Safer, Efficacious Therapies

  • Daniel Shelly Chief Business Development Officer, PolTREG Immuthera
  • Luke Devey Chief Medical Officer, Quell Therapeutics

Synopsis

  • Expand therapeutic approaches beyond B-cell depletion
  • Highlight safety challenges with depletion in comparison to tolerance with Tregs
  • Explore the long-term biological effects of B-cell depletion and immune reprogramming therapies

Optimizing Immune Cell Depletion Strategies to Enhance Safety, Persistence & Long-Term Remission in Autoimmune Therapies

1:10 pm Advancing T-Cell-Targeted Therapies for Autoimmune Diseases to Unlock More Precise & Durable Treatment Options

Synopsis

  • Explore T-cell targeting strategies to combat SLE and improve therapeutic outcomes
  • Examining Novartis’ srSLE CAR-T data to uncover insights into novel CAR-T approaches to address unmet medical needs
  • Highlight Novartis’ novel CAR-T manufacturing platform (T-Charge) to evaluate its impact on enhancing T-cell targeted treatments for autoimmune diseases

1:40 pm Panel Discussion: Utilizing Biomarkers to Sustain Durable Responses in Autoimmune Therapies

  • Susanne Diehl Head, Global Program & Immunology, Novartis AG
  • Phung Gip Senior Director & Head of Translational Medicine, Nkarta Inc
  • Jenell Volkov Senior Director - Translational Medicine, Cabaletta Bio

Synopsis

  • Identify the capacity of biomarkers to predict therapeutic responses
  • Harness specific biomarkers to effectively identify patient response, manage patient safety and enhance patient selection
  • Explore the use of biomarkers to determine optimal timing for re-dosing and sustaining efficacy

2:30 pm Afternoon Break & Poster Session

Synopsis

This is your opportunity to contribute to the conversation and share your cutting-edge research with this community, while discovering exciting work carried out by your peers. To submit a poster, please contact info@hansonwade.com.

Delving into Cell Therapy Innovations to Explore the Future of Autoimmune Cell Therapies

3:30 pm Demonstrating Durable Remission in Lupus with iCell Gene Therapeutics’ Dual-Target, Armored CAR-T Therapy

Synopsis

  • Introducing iCell Gene Therapeutics’ ICG318 CD-19—BCMA/IL-15 compound CAR-T
  • Evaluate the synergistic impact of combined B-cell and plasma cell depletion in enhancing durability of response
  • Highlight iCell Gene Therapeutics’ 5+ year long-term follow-up data, to define what therapeutic durability looks like in lupus patients

4:00 pm Keynote Presentation: Reserved for Umoja Biopharma

4:30 pm Advancing In Vivo RNA Therapies Towards Clinical in B-Cell-Mediated Autoimmune Diseases

  • Gilles Besin Chief Scientific Officer, Orbital Therapeutics

Synopsis

  • Share data highlighting the benefits of in vivo therapies in autoimmune diseases
  • Share NHP preclinical data highlighting the benefits of in vivo RNA therapy
  • Highlight the development of in vivo CAR-T therapy for the clinic

5:00 pm Chair’s Closing Remarks

  • Fred Aslan President & Chief Executive Officer, Artiva Biotherapeutics, Inc

5:15 pm End of Conference Day One